Loading stock data…
$10.26-0.13 (-1.25%)
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Zevra Therapeutics, Inc. in the Healthcare sector is trading at $10.26 with a market capitalization of $609M. Wall Street consensus targets $25.00 (9 analysts), implying a +143.7% move over the next 12 months. The stock is currently 32% below its 52-week high of $15.04, remaining 3.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $39.66M↑ | $36.22M↑ | $34.13M↑ | $26.06M↑ | $25.88M |
| Gross Profit | $38.14M↑ | $34.32M↑ | $32.60M↑ | $24.82M↑ | $13.50M |
| Operating Income | $16.78M↑ | $8.83M↓ | $9.31M↑ | $4.14M↑ | -$12.33M |
| Net Income | $8.75M↓ | $37.89M↑ | $12.16M↑ | -$544,000↓ | $74.71M |
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidat...